The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians, academicians, allied health professionals,...
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Pandemic-linked decline in cancer screening persisted Into 2022
Feb 06, 2023
Low-dose computed tomographic scan rates and mammography rates were lower than expected during March 2021 to February 2022.
Study looks at extent of residual lung abnormalities after COVID-19 hospitalization
Dec 02, 2022
The posthospitalization prevalence of residual lung abnormalities was estimated at 11.7% in sensitivity analyses.
Minorities with dementia show lower incidence of amyloid PET positivity
Oct 12, 2022
The authors say that the findings have implications for treating dementia unrelated to amyloid plaques.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
Seizures in young stroke survivors double dementia risk
Jul 29, 2022
The findings were seen for all strokes, ischemic strokes and hemorrhagic strokes.
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Higher habitual coffee intake may slow cognitive decline
Nov 30, 2021
Higher baseline coffee consumption also was linked to slower Aβ-amyloid accumulation during a 126-month study period, as shown on brain MRI scans.